Biopharmaceutical company Medicago and drug maker GlaxoSmithKline reported Tuesday positive efficacy and safety results from the Phase 3 trial of their plant-based COVID-19 vaccine.

“Medicago, which is headquartered in Quebec, reported in a news release that their Phase 3 placebo-controlled study — conducted in more than 24,000 subjects in six countries who are 18 and older — reported an overall vaccine efficacy rate of 71 per cent against all variants of SARS-CoV-2 which were circulating at the time of the study.

“Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-2 variants unlike most published Phase 3 efficacy trials for currently licensed COVID-19 vaccines that were conducted when only the ancestral virus was circulating,” the release states.”

https://www.ctvnews.ca/health/coronavirus/canadian-made-plant-based-covid-19-vaccine-sees-positive-phase-3-results-1.5696558